223 related articles for article (PubMed ID: 28004883)
1. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
[TBL] [Abstract][Full Text] [Related]
3. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
4. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
5. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Ueda H; Hayashi H; Kudo K; Takeda M; Nakagawa K
Invest New Drugs; 2016 Dec; 34(6):797-799. PubMed ID: 27550238
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.
Sala González MÁ
Cancer Biol Ther; 2015; 16(10):1434-7. PubMed ID: 26186355
[TBL] [Abstract][Full Text] [Related]
8. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
[TBL] [Abstract][Full Text] [Related]
9. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Saxon JA; Sholl LM; Jänne PA
J Thorac Oncol; 2017 May; 12(5):884-889. PubMed ID: 28088511
[TBL] [Abstract][Full Text] [Related]
10. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
11. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Fujiwara A; Yoshida M; Fujimoto H; Nakahara H; Ito K; Nishihama K; Yasuma T; Hataji O; Taguchi O; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
Oncol Res; 2018 Aug; 26(7):1031-1036. PubMed ID: 29321093
[TBL] [Abstract][Full Text] [Related]
13. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
[TBL] [Abstract][Full Text] [Related]
16. Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Vitale MG; Scagliarini S; Riccardi F; Barbato C; Otero M; Mocerino C; Ambrosio F; Cartenì G
Tumori; 2015 Apr; 101(2):e64-6. PubMed ID: 25702672
[TBL] [Abstract][Full Text] [Related]
17. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
18. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
19. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Li SH; Hsieh MH; Fang YF
Medicine (Baltimore); 2015 Oct; 94(41):e1739. PubMed ID: 26469914
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Sárosi V; Balikó Z
Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
